NeoNC Technologies Reveals Updated Clinical Results
In an updated dataset of 24 patients with recurrent WHO grade III/IV IDH1‑mutant astrocytoma treated with intranasal NEO100, radiographic...
Reviva Reveals New Anti-Inflammatory Hope for Schizophrenia
No new efficacy or safety figures were released. Still, Reviva will present late-breaker data on biomarker shifts with brilaroxazine...
P84 Study: A Breakthrough for Gut Peptide Production
In a third-party in vitro study across four gut cell types, LifeVantage’s P84 formula reportedly modulated 14 gut-relevant peptides...
Intellia’s New HAE Drug Delivers Successful Phase 1/2 Data
Among 32 patients with hereditary angioedema (HAE) who received a one-time 50 mg IV dose of Intellia’s in vivo...
Anaptys Rosnilimab Fails Ulcerative Colitis Phase 2 Trial
Rosnilimab failed to improve outcomes over placebo at Week 12 in a 136‑patient Phase 2 ulcerative colitis study, with...
New Data on DLL3 Radiotherapy MP0712 Shown in Human Images
First-in-human imaging with 203Pb-labeled MP0712 showed focal uptake in primary and metastatic lesions at 24 hours, sustained through day...
Remarkable New Heart Data Revealed in iRhythm Study
In a retrospective analysis of 1.1 million ambulatory ECG records, 64% of patients with daily symptoms and actionable arrhythmias...
AIM Details New UPMC Trial of Ampligen in Ovarian Cancer
A Phase 2 study in platinum-sensitive recurrent ovarian cancer reported a 50% objective response rate among 24 evaluable patients...
BioCardia, Henry Ford Health Begin Phase 3 Cell Therapy Trial
In BioCardia’s prior CardiAMP-HF study, the composite primary endpoint was achieved with statistical significance in the subgroup of ischemic...
Ernexa Therapeutics Reports Strong Q Performance, Cell Trials
Ernexa reported a 58.2% survival advantage in preclinical models for its ovarian cancer program, ERNA-101, and a 44% year-over-year...